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Risk-adapted dental care 
prior to intensity-modulated 
radiotherapy (IMRT)
Results
Key words: dental care before radiotherapy, osteoradionecrosis
Introduction
In keeping with international guidelines (Grötz 2003; Shaw 
et al. 2000), all head-and-neck tumor (HNT) patients at our 
clinic since more than two decades have undergone standard-
ized focal evaluation and dental treatment prior to all radiation 
therapy.
Since 01/2002, our HNT patients have been treated with in-
tensity-modulated radiotherapy (IMRT) (n > 800, status: March, 
2010). The greatest clinical advantage of this relatively new 
technique is that it causes substantially less damage to normal 
tissues while providing equally good or improved tumor con-
trol rates (Lee et al. 2002; Eisbruch et al. 2003; Eisbruch et 
al. 2004; Chao et al. 2004; De Arruda et al. 2006; Puri et al. 
2005; Studer et al. 2006a–c, Studer et al. 2007c/d).
Details of the IMRT technique were explained in an earlier 
publication (Studer et al. 2007a, Tab. I and Fig. 1). Even in 
the first years after implementation of IMRT a diminishment 
Summary Background: At the Clinic for 
 Radiation Oncology at the Zurich University 
Hospital (UniversitätsSpital Zürich [USZ]), 
head-and-neck tumor (HNT) patients have 
been treated with intensity-modulated radio-
therapy (IMRT) since 01/2002 (n > 800). This 
method causes less damage to normal tissues 
adjacent to the tumor, and thus it was possible 
in the head/neck region to markedly reduce 
the rate of osteoradionecrosis (ORN), in addi-
tion to reducing the rate of severe xerostomia. 
Based on these results, risk-adapted dental 
care (RaDC) was adopted by our clinic as the 
standard mode of pre-IMRT dental treatment. 
The guidelines as formulated by Grötz et al. 
were respected.
ORN prophylaxis is one of the most important 
goals of pre-radiotherapy dental care, and the 
ORN rate is a measurable parameter for the 
efficacy of dental care, given a certain radia-
tion technique. The aim of the present study 
was therefore to evaluate the efficacy of RaDC 
as reflected by the ORN rate of our IMRT pa-
tients.
Materials and Methods: In August 2006, RaDC 
was clinically implemented and has been 
used for all HNT patients prior to IMRT since 
then. Before that (01/2002–07/2006), dental 
restorations were performed according to the 
usual procedure.
Results: The rate of grade-2 ORN was similar 
in the conventionally treated and RaDC groups 
(2% and 1%, resp.); grade-3 ORN had not 
occurred by the time the analysis was con-
ducted. As expected, fewer extractions were 
performed in the RaDC cohort (no extractions 
in 47% of the RaDC/IMRT cohort vs. 27% in 
the IMRT cohort receiving conventional dental 
care).
Conclusion: After considerably less invasive 
dental treatment, no higher-grade ORN oc-
curred and no ORN-related jaw resections 
were required. Based on the present data, 
risk-adapted minimally invasive dental care is 
recommended before IMRT.
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of radiation. The hypothesis tested was that a constantly low 
ORN rate would be found in IMRT patients after RaDC com-
pared to IMRT patients who received conventional dental treat-
ment.
Materials and Methods
Patient cohorts
In the present study, two patient groups were compared (Tab. III): 
in group 1, from January 2002 to July 2006, 143 HNT patients 
were given conventional dental care with standard restorations 
prior to IMRT: 100 patients with oropharyngeal carcinoma and 
43 with a carcinoma of the oral cavity. The mean/median 
observation period of this group was 40/33 months (5–86).
In group 2, between August 2006 and December 2008, 161 
patients received IMRT: 106 with oropharyngeal carcinoma and 
55 with oral cavity carcinoma. With all patients risk-adapted den-
tal care (RaDC) was performed prior to IMRT. The mean/me-
dian observation period of this group was 19/13 months (6–44).
of the greatly feared osteoradionecrosis (ORN) was observed 
(Glanzmann & Grätz, 1995; Studer et al. 2004; Studer et al. 
2006d; Studer et al. 2007a; Ben-David et al. 2007). In con-
trast to conventional radiation techniques, as applied to a 
tonsil carcinoma for instance, in which the jawbone is at risk 
bilaterally due to laterally opposing radiation beams, IMRT can 
much more selectively deliver the required dose to the tumor 
region. During IMRT of tonsil carcinoma the contralateral 
jawbone is no longer endangered and the ipsilateral much less 
so. Hence, adapting Grötz’s (Tab. II) guidelines for focused 
dental care seemed expedient (Tab. I). This adapted method, 
termed “risk-adapted dental care” (RaDC), has been employed 
on our IMRT patients since mid-2006 (Studer et al. 2007b). It 
requires that ORN risk areas, i. e. IMRT high-dose areas on the 
jawbone, be topographically defined by the radiation oncolo-
gist prior to dental treatment. Areas with low and intermediate 
ORN risk are also defined for the dentist, so that dental resto-
rations can be performed conventionally in high-risk areas, 
but less invasively in the regions that will receive lower doses 
Dental Care prior to IMRT 
risk definition 
(to be marked by the responsible radiation oncologist)
High Risk area: HR (in red)
Intermediate / Low Risk area: MNR (in green)
No Risk: NR (in yellow)
UniversitätsSpital Zürich
D
ept. M
edizinische Radiologie 
Klinik für Radio-O
nkologie Zürich
Radiation 
oncologist: ……………… 
Pager
Patient ID label
Diagnosis / TNM 
stage: ………………………
Fig. 1 (corresponds to Tab. I): Zurich University Hospital’s internal form for marking (IMRT dosage-dependent) individual risk areas for dental treatment before 
intensity-modulated radiation therapy (IMRT). The risk areas (high, intermediate/low, no risk of jaw osteonecrosis) for each patient are marked by the radiation 
oncologist as the basis for the dental treatment planned (see Tab. I). 
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areas, i. e. high ORN-risk areas, prior to treatment, the dentist 
can use this information to know regions requiring risk-adapted 
dental care in each individual patient (see Studer et al. 2007b). 
The patient form used for marking risk areas for RaDC is shown 
in Figure 1 and Table I.
a) High-risk regions:
 60 Gy to the mandibular bone and/or > 50 Gy to gingival 
areas.
b) Intermediate-risk regions:
> 45 Gy to the gingiva, mandibular bone < 60 Gy, or: man-
dibular bone < 60 Gy, and relevant reduction of salivation 
caused by irradiating mucous membranes and salivary glands 
(no ORN risk, but increased caries risk – for instance after cer-
tain types of cervical irradiation in Hodgkins lymphoma).
c) Low-risk regions:
Mandible < 60 Gy or only ascending ramus in the RT field, and 
gingiva < 45 Gy and at least a parotid volume equivalent with 
an intermediate dose of  26 Gy.
d) No radiotherapy-specific risk:
Mandibular bone < 50 Gy, gingiva < 40 Gy, and both parotids 
outside the RT field (< 10 Gy intermediate dose).
Examination for ORN (Tab. IV) was conducted as part of the 
routine oncological follow-up examinations (by the clinics 
for Oral and Maxillofacial Surgery, ENT, and Radiation Oncol-
ogy, University Hospital, Zurich) that were performed regularly 
4–6 weeks after completion of treatment, then every 2 to 
3 months during the first 2 years. In suspected or positively 
identified cases of ORN patients are referred to the Clinic for 
Maxillofacial Surgery for further evaluation and treatment.
Only patients at risk of developing ORN – that is, patients 
with a tumor of the oropharynx (n total = 206) and the oral 
cavity (n total = 98) – were evaluated.
Methods
The ORN incidence in the clinic’s IMRT cohort since RaDC was 
introduced (08/2006–12/2008, group 2) was compared with 
the incidence after conventional dental treatment (01/2002–
07/2006, group 1). We expected to find an unchanged, low 
incidence of ORN in group 2 vs. group 1, since ORN occurs in 
areas exposed to high doses (usually at doses > 66 Gy), in which 
lesion extirpation was performed according to the usual stan-
dard.
Based on the various known tolerance thresholds of different 
normal tissues for a given radiation dose, it was possible to 
define the risk level for patients scheduled for oral cavity ra-
diation treatment (see below, a–d). Because the radiation on-
cologist can identify and mark topographic IMRT high-dose 
 Before radiotherapy During radiotherapy After radiotherapy
 Dental treatment Tissue-conserving treatment Tissue-conserving treatment
 – Removal of hard and soft plaque – Mucosa retractors (reduction of surface – Continuation of fluoride application 
 – Extraction of nonvital, periodontally    dose to adjacent mucosa via secondary – Discontinuation of prosthesis wearing for 
   diseased, carious, partially retained teeth   irradiation)   3–6 months after irradiation 
 – Conservative treatment of remaining  – Fluoridation splint and continuous fluoride – Tooth- or implant-borne prostheses or 
   dentition   rinsing   maxillary prostheses can be re-inserted 
 – Surgical treatment of  – Temporary discontinuation of prosthesis   earlier, after mucositis has subsided 
   – mucosal lesions   wearing due to sore spots or denture ulcers – Restoration of masticatory function is often 
   – removal of sharp bone ridges  – Mucositis prophylaxis especially due to   impossible due to xerostomia or jaw lesions 
     (mylohyoid line)   xerostomia (Candida colonization) – Special guidelines for dental surgery after 
 Extent of extractions depends on inclusion    – Bepanthen®   radiotherapy to avoid osteoradionecrosis:
 of salivary glands in the irradiated field; four    – topical antimycotics   – Perioperative, systemic antibiotic prophy- 
 groups:     (Nystatin = Moronal®)     laxis (e. g., Amoxicillin), at the latest 24 h
 – Edentulous patients without mucosal    – mouth rinses (chamomile, sage,     pre-operatively 
   lesions = no pre-irradiation therapy     chloramine tea); Sucralfat suspension   – Atraumatic tooth extraction without 
 – If conservative treatment is impossible – Diflucan® (local & systemic yeast infections)     osteotomy, if possible
   = total extraction, clearing – Discontinue consumption of external noxae – Removal of sharp bone ridges 
 – Conservative caries treatment possible   – alcohol, nicotine – Primary plastic mucosal closure 
   = elective extraction   – no hot, spicy, or acidic drinks – Xerostomia treatment 
 – No active caries, good oral hygiene  – Dermatitis prophylaxis – Artificial saliva (warning: Glandosan®
   = no tooth extractions – Mouth-opening exercises, if masticatory   = mineral loss; mucine-containing 
    muscles and TMJ lie in irradiated field   Saliva-medac® and lysozyme-containing
  – Xerostomia treatment   BioXtra® products)
  – Ethyol (Amifostin®) or Cumarin/Troxerutin – Salivary gland stimulants Sialor®
    (Venalot-Depot®) – Mouth-opening exercises against trismus
Tab. II Dental care of patients receiving radiotherapy for head-and-neck tumors (Grötz K A, Strahlenther Onkol 2003; 
179 [4]: 275–278)
Co
nv
en
ti
on
al
 r
ad
ia
ti
on
 t
he
ra
py
Parameter Group 1 Group 2 
 n = 143 n = 161
Dental treatment standard RaDC
RT technique IMRT IMRT
Timespan of treatment  1/2002–7/2006 8/2006–12/2008
Diagnosis
 Oropharynx (n = 206) 100 106 
 Oral cavity (n = 98) 43 55
Average/median 
FU time in months 40/33 19/33
Tab. III Overview comparing the two subgroups of  
patients. RT: radiotherapy; FU: follow-up; RaDC: risk-
adapted dental care
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5 cases observed also correspond to the NCI and EORTC classi-
fication of a grade-2 ORN. Table Vl presents details on the 
5 sequester patients. All ORN events were found in the high-
dose region. Other, unexpected reactions of the mucosa or 
teeth outside the high-dose areas were not observed; the less 
invasive tooth restorations outside the high-dose areas in 
RaDC group 2 did not demonstrate any clinically apparent, 
unfavorable results.
Tooth extractions
Table VII lists the number of teeth extracted in each group. As 
expected/by definition, fewer teeth were extracted in the RaDC 
cohort. In this context, the clinically relevant (but not quanti-
fied) fact must be mentioned that almost no radiation plann-
ing computed tomography (“planning CT”) had to be delayed 
due to pronounced facial soft-tissue swelling after multiple 
extractions performed as part of the prior dental care. This was, 
however, frequently the case in the period of conventional 
dental treatment (group 1), with an ensuing delay of 1 to 2 weeks 
until the swelling had gone down; thus, the start of radio-
therapy was also delayed.
In addition, a tendency of more frequently possible dental 
rehabilitation was observed (no statistical analysis of these 
retrospective data).
Discussion
In addition to severe xerostomia, ORN is the most important 
criterion for radiation tolerance in oral cavity and oropharyn-
geal carcinoma patients, and is the main justification for 
consistently performing dental treatment prior to the start of 
radiotherapy. Comprehensive dental and/or oral surgery treat-
ment prior to radiotherapy in the orofacial region is of funda-
mental importance in the prevention of osteonecrosis of the 
irradiated jaw.
ORN has been variously classified according to different 
definitions in earlier publications. In our clinics, the classifica-
tion by Glanzmann and Grätz is used (Glanzmann & Grätz 
1995, Tab. lV). The advantage of this classification vs. that of 
EORTC (LENT/SOMA) or NCI (Jereczek-Fossa et al. 2002) is 
its connection to therapeutic and clinical consequences; 
nevertheless, grade-2 events mutually correspond in all of the 
named classification systems.
With the radiotherapeutic technology of the past the re-
quired tumor dosage was chiefly delivered via laterally opposed 
fields, which also simultaneously irradiated most of the oral 
Only three patients in this study group failed to participate 
in the routine progress check-ups, and therefore could not be 
evaluated.
Results
Tumor control
In 90% of the patients, chemotherapy (Cisplatin or Cetuximab) 
was also performed simultaneously. At the last performed fol-
low-up examination (“last time seen”), 74% of the patients 
were living tumor-free, 12% were living with cancer, 12% had 
died of cancer, and 3% had died of other causes. The 2-year 
local control rate of the entire patient group was 85% among 
patients with oropharyngeal cancer, and 65% among patients 
with cancer of the oral cavity.
ORN incidence
ORN incidence is shown in Table V. The rates of grade-2 ORN 
(sequester formation) were identical in groups 1 and 2; all 
Classification of osteoradionecrosis (ORN) by grade
Grade Event
1 Exposed bone without signs of infection for at least 
 3 months
2 Exposed bone with signs of infection or sequester, but not
 grades 3–5
3 Osteonecrosis, treated with mandibular resection, with 
 satisfactory result
4 Osteonecrosis with persistent problems despite mandibular 
 resection
5 Death due to osteoradionecrosis
Tab. IV Grades of osteoradionecrosis (Glanzmann & 
Grätz 1995)
 conventional risk-adapted
 1/2002–7/2006 8/2006–12/2008 Total 
 n = 143 n = 161 n = 304
Grade-1 ORN 0 0 0
Grade-2 ORN 3 2 5 (1.6%)
Grade-3 ORN 0 0 0
Tab. V Occurrence of osteoradionecrosis (ORN) after 
conventional or risk-adapted dental care (RaDC)
 Diagnosis Stage ORN location ORN therapy outcome Occurrence Duration 
      after IMRT (months)
1 Oropharynx cT4cN2c Boost region O Healed 12 20
2 Oropharynx cT3cN2b Boost region Partial decortication Regenerated  4  5
3 Oropharynx cTcN2b Boost region O Healed 22 30
4 Floor of mouth pT2pN0 Boost region Partial decortication Regenerated  0  6
5 Oropharynx cT3cN2b Boost region O Healed  6 20
Patients 4 and 5 received risk-adapted dental care (RaDC) before IMRT 
In terms of local radiation dose, nothing remarkable was found compared to other patients without ORN. 
The 5 events were located in region 37/retromolar left/31–32/37/47. 
pTpN: postoperative stage 
cTcN:  definitive IMRT without prior surgery
Tab. VI Details on the 5 patients with grade-2 ORN: comparable grade-2 ORN rates in oropharyngeal and oral-cavity 
cancer patients with 2% (4/206) vs 1% (1/98), resp.
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Parameter Conventional dental care RaDC 
 (IMRT group 1) (IMRT group 2)
Edentulous patients 17% 15%
Dentate patients
– no extractions 27% 47% 
– 1–3 teeth extracted 36% 29% 
– 4–15 teeth extracted 37% 24%
Dental rehabilitation 23% 36%
Tab. VII Retrospective overview of the number of teeth extracted during dental treatment prior to radiotherapy and  
during dental care after IMRT (dental implants, removable partial or complete dentures) 
cavity and/or jawbone. This resulted in a greater radiation 
impact on the jawbone, associated with a higher ORN rate, 
than seen today in the IMRT era; accordingly, the entire den-
tate jaw usually had to be considered a “region at risk” and 
correspondingly dentally treated. IMRT is a method which 
makes it possible to restrict the high-risk region to the volume 
of jawbone adjacent to the tumor. IMRT enabled the ORN rate 
to be reduced from ca. 5–10% to  1% (Glanzmann & Graetz, 
1995; Studer et al. 2004; Studer et al. 2006d; Studer et al. 
2007a; Ben-David et al. 2007), a success of considerable rele-
vance in the attempt to reduce late complications of radiation 
treatment. The “focussed” high-dose exposure and the pro-
nounced drop in the ORN rate after IMRT shown in our patients 
in 2006 indicated the logic of also keeping dental treatment 
“focussed”, which our center has therefore done since mid-
2006. Table I shows the steps of dental treatment in RaDC: ad-
aptation of methods to the local risk for jawbones and soft tis-
sues before/during/after IMRT; Table II summarizes the standard 
procedures which have existed up to now. As already mentioned, 
the main difference lies in the focussed approach of RaDC.
After an observational period of over 3 years since introduc-
ing the guidelines for pre-IMRT RaDC, no detrimental effects 
have yet been found in patients of group 2, most importantly, 
no increase in ORN incidence compared to the IMRT group 1, 
which in the previous years had undergone focal treatment ac-
cording to the conventional standard. Although the duration 
of observation differed in the two groups, the results are con-
sidered reliable because both groups are IMRT cohorts, i. e., it 
was possible to very conservatively treat jawbones in both 
groups and include only relatively low volumes of bone in the 
high-dosage area. Thus, due to the use of the IMRT technique, 
an increase in ORN was not expected. As already mentioned, 
dental treatment in the high-risk regions in the RaDC groups 
was also performed in accordance with the general standard. 
Less invasively treated intermediate or low-risk areas by defini-
tion receive intermediate or very low radiation doses, so that, 
theoretically, only limited side-effects are expected in these 
tissue areas in RaDC group 2. In fact, 3 years of RaDC experi-
ence confirmed this. However, due to the paucity of data in 
literature, comparisons cannot be made.
Thanks to RaDC, it was possible to reduce the number of or 
even totally avoid tooth extractions in the majority of patients 
(50% more patients with no extractions, Tab. VII), since IMRT 
creates more low- and intermediate-risk areas (that would 
previously have been high-dose areas), allowing less invasive 
dental treatment to be performed.
In this context, the rarity of facial swelling after RaDC is also 
clinically relevant. This is yet another advantage of RaDC, 
since time is no longer lost waiting for swelling to abate: the 
planning CT serves as the basis for computer-assisted 3-dimen-
sional calculation of radiation dose delivery to the tissues/tu-
mor, and is performed as soon as possible after dental treat-
ment. This CT is conducted with a custom-modelled fixation 
facial mask made of plastic (for the purpose of reproducibly 
positioning the patient over the weeks of treatment, every 
radiotherapy session is carried out using this mask). If the mask 
is made on a swollen face, it will be loose after the swelling has 
subsided; both the fixation mask and the millimeter-exact 
radiation plan are thus rendered worthless.
 Experience has shown that careful manipulations/interven-
tions on the jawbone and its mucous membrane covering are 
well tolerated after radiation doses of up to ~ 50 Gy, but at 
doses over > 50 Gy, invasive interventions are accompanied by 
an increased risk of ORN and lower tissue tolerance. If the 
status of the remaining dentition and surrounding tissues is 
better, this greatly improves the outlook for any subsequent 
dental care, which in turn positively influences the tumor 
patient’s quality of life (Zwahlen et al 2008). The retrospective 
data on dental treatment seems to confirm this (Tab. VII).
From an economic point of view, avoiding a grade-3 or 
-4 ORN amounts to a savings of about € 30,000 (based on Swiss 
conditions); the improved possibilities for dental treatment 
and the advantages of more remaining teeth are more difficult 
to express in terms of costs. Nevertheless, the health advan-
tages and improved quality of life for the patients are indisput-
able. It is interesting to note that the incidence of bisphospho-
nate-associated osteonecrosis currently considerably exceeds 
that of ORN after IMRT (18.6%, Walter et al. 2008; Dannemann 
et al. 2008).
Conclusion
Following much less invasive dental treatment, no higher-
grade ORN or ORN-related jaw resections occurred in our IMRT 
patient cohort, as before. The more invasive standard guide-
lines for dental treatment prior to radiotherapy which have 
been valid up to now no longer appear justifiable for IMRT 
patients. Based on the data presented here, a risk-adapted, less 
invasive approach to pre-IMRT dental care is recommended.
Résumé
Introduction: L’IMRT est implémentée au Département de 
radio-oncologie de l’Hôpital de Zurich depuis 2002. Outre une 
diminution de la xérostémie, son avantage principal dans les 
régions de la tête et du cou réside dans une réduction substan-
tielle du RON (de ~ 5–10% à ~ < 1%).
Les procédures standards lors des soins dentaires préradio-
thérapeutiques ont été ajustées afin d’être moins invasives 
pour les patients soumis à l’IMRT depuis août 2006.
Patients et méthode: Cet article présente les résultats d’une 
période d’un suivi de 3 ans pour des patients qui ont reçu des 
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soins dentaires adaptés aux risques avant l’IMRT pour des 
cancers de la tête et du cou (n = 161). Des patients traités avec 
des soins dentaires standards (n = 143) avant l’IMRT de 01/2002 
à 07/2006 ont servi de contrôle.
Résultats: Les analyses du RON ont révélé des taux d’inci-
dence égaux pour les deux périodes (1,5% degré 2, pas d’oc-
currence de degré 3, et pas de résection de la mandibule), et 
moins d’extractions dentaires grâce au traitement dentaire 
adapté aux risques.
Conclusion: Sur la base des données présentées ici, le traite-
ment dentaire adapté aux risques est fortement recommandé 
pour les patients soumis à l’IMRT.
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